Introduction:

The results of the ABSORB trial showed the efficacy and safety of bioresorbable vascular scaffolds (BVS) and their unique advantage, namely, the restoration of vasomotion after full biodegradation.

Objectives:

The aim of the registry was to evaluate procedural issues, angiographic results, and clinical outcomes of patients with acute coronary syndrome (ACS) treated with BVS implantation.

Patients and methods:

The study included 100 patients. Cohort 1 comprised 46 patients with unstable angina; cohort 2, 38 patients with non‑ST‑segment elevation myocardial infarction; and cohort 3, 16 patients with ST‑segment elevation myocardial infarction.

Results:

Predilation was performed in 93% of the patients. The final Thrombolysis In Myocardial Infarction (TIMI) 3 flow was achieved in 99% of the patients. In all patients, BVS was successfully implanted. In 81% of the patients, postdilation was performed with a balloon catheter with the same diameter as BVS; in 11%, with a balloon catheter with a diameter of 0.25 mm larger than BVS; and in 7%, with a balloon catheter with a diameter of 0.5 mm larger than BVS. We observed no no‑reflow phenomenon, 1 distal embolization, and 2 slow‑flow phenomena. Two major adverse cardiac events were reported, namely, periprocedural myocardial infarction in 2 patients. During 1‑year follow‑up, we observed only 1 additional myocardial infarction caused by stent thrombosis as well as 1 target lesion revascularization.

Conclusions:

In our study, BVS in patients with ACS showed to be a safe and effective procedure.